TuHURA Biosciences, Inc./NV (HURA): Nasdaq/NYSE listing notice — TuHURA receives Nasdaq delisting notice for bid price below $1.00; 180-day cure period until July 2026

TuHURA Biosciences, Inc./NV

Nasdaq letter on Jan 29, 2026, for bid price <$1.00 for 35 consecutive days, violating Listing Rule 5550(a)(2).
Company has 180-day grace period, until July 28, 2026, to regain compliance by closing bid price ≥$1.00 for 10 consecutive days.
If not compliant by July 28, a second 180-day period may be available if other listing standards are met.
Company will monitor bid price and consider options, including a potential reverse stock split to regain compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

TuHURA Biosciences, Inc./NV received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

January 29, 2026, TuHURA Biosciences, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s consolidated closing bid price has been below $1.00 per share for 35 consecutive business days as of January 28, 2026, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which is the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. Pursuant to Nasdaq Listing R

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0001193125-26-031742

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.